Analysts Anticipate Hologic, Inc. (HOLX) Will Post Quarterly Sales of $791.68 Million

Wall Street brokerages expect Hologic, Inc. (NASDAQ:HOLX) to report sales of $791.68 million for the current quarter, Zacks reports. Six analysts have made estimates for Hologic’s earnings, with the highest sales estimate coming in at $794.50 million and the lowest estimate coming in at $787.40 million. Hologic reported sales of $715.40 million in the same quarter last year, which indicates a positive year over year growth rate of 10.7%. The company is scheduled to announce its next earnings results on Wednesday, May 9th.

According to Zacks, analysts expect that Hologic will report full-year sales of $791.68 million for the current fiscal year, with estimates ranging from $3.24 billion to $3.27 billion. For the next fiscal year, analysts expect that the company will report sales of $3.40 billion per share, with estimates ranging from $3.37 billion to $3.44 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Hologic.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. The company had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.75%. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 earnings per share.

A number of brokerages have issued reports on HOLX. Needham & Company LLC restated a “buy” rating and set a $50.00 target price (up previously from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Deutsche Bank downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Friday, January 19th. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price target for the company in a report on Wednesday, December 20th. Finally, Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $48.36.

In other news, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. Insiders own 0.79% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Hall Laurie J Trustee grew its holdings in Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the period. Sentry Investment Management LLC grew its holdings in Hologic by 1.9% in the second quarter. Sentry Investment Management LLC now owns 18,491 shares of the medical equipment provider’s stock valued at $839,000 after purchasing an additional 353 shares during the period. Creative Planning grew its holdings in Hologic by 8.2% in the fourth quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock valued at $658,000 after purchasing an additional 1,161 shares during the period. AT Bancorp grew its holdings in Hologic by 2.2% in the fourth quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock valued at $2,664,000 after purchasing an additional 1,323 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its holdings in Hologic by 0.3% in the third quarter. State Board of Administration of Florida Retirement System now owns 406,630 shares of the medical equipment provider’s stock valued at $14,919,000 after purchasing an additional 1,351 shares during the period. Hedge funds and other institutional investors own 92.77% of the company’s stock.

Hologic (HOLX) opened at $37.75 on Friday. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. The stock has a market cap of $10,729.33, a PE ratio of 9.96, a price-to-earnings-growth ratio of 1.81 and a beta of 0.77. Hologic has a 52-week low of $35.33 and a 52-week high of $46.80.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/11/analysts-anticipate-hologic-inc-holx-will-post-quarterly-sales-of-791-68-million.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply